Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Slides:

Advertisements

Similar presentations

Luigi Oltrona Visconti Divisione di Cardiologia IRCCS Fondazione Policlinico S. Matteo Pavia Sindromi coronariche acute nei pazienti con fibrillazione.

Advertisements

The patient with atrial fibrillation who needs PCI

Denise Sutter, PharmD, BCPS

When should aspirin be dropped from triple therapy?

Addressing the Challenges in Primary and Secondary Stroke Prevention

Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.

PCSK9 Inhibitors Post-CVOTs

Preventing Thrombotic Complications in ACS: State of the Art

Atrial Fibrillation and PCI

Anticoagulants in Interventional Cardiology:

Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Updates in Anticoagulation: What Did We Learn From ESC 2017?

US Guidelines US Guidelines Low-risk Patients.

NOACs, AF, and PCI: What Do the Latest Data Suggest?

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Barriers to Oral Anticoagulant Use for Stroke Prevention in AF

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Anticoagulation Highlights From the American Heart Association Meeting 2017.

Up to Date on Which NOAC for Which Patient

New Perspectives in AF and PCI: Implications for the Practicing Physician.

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Antithrombotics and PAD: A New Paradigm in Practice

New Perspectives in CAD and PAD: Weighing the Latest Evidence

Surveying the Safety of NOACs in the Real World

Selecting NOACs for High-Risk Patients

Antiplatelet Therapy and Secondary Prevention

NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS

The Essentials for Secondary Stroke Prevention

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

NOACS: Emerging data in ACS/IHD

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

TAVR and the Risk of Thrombosis

What Anticoagulant Registries Are Revealing

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Reversal Strategies for VKA: Truths and Misconceptions

Practical Considerations to Extend Treatment for VTE

Atrial Fibrillation.

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Anticoagulation and Thrombosis Management

Assessing Atrial Fibrillation: Real-World Data vs Clinical Trials

Duration of Dual Antiplatelet Therapy

A Time for Change for Managing Patients With VTE Who Have Cancer

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Updates in Anticoagulation: Key Sessions at ESC 2017

NOAC Studies in VTE AF Studies Superior Outcomes.

Iron Deficiency in Heart Failure

Antithrombotics in Arterial Disease: Focus on Coronary Disease

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.

Disease Burden of VTE Phases of VTE Treatment.

5 Good Minutes on Atrial Fibrillation-related Stroke

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

ESC Guideline on the Management of STEMI Recommendation for DAPT

Key Data on Improving Outcomes in HF Patients

Extraordinary Cases in Stroke Prevention

Antithrombotic Therapy in AF Patients Undergoing PCI

What's New in NOACs in AF?.

Presentation transcript:

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Patients with AF Undergoing PCI: Background

WOEST Study Design

WOEST - VKA in Patients With AF Undergoing PCI Any Bleeding

WOEST - VKA in Patients With AF Undergoing PCI Efficacy

PIONEER AF-PCI Study Design

PIONEER AF-PCI: Outcomes

PIONEER AF-PCI MACE (All Participants)

PIONEER AF-PCI Dosing Strategies

PIONEER AF-PCI Post-Hoc Analysis: All Cause Mortality and Recurrent Hospitalization

RE-DUAL PCI Study Design

RE-DUAL PCI Primary Endpoint - Bleeding

RE-DUAL PCI Individual Thromboembolic Endpoints

AUGUSTUS Study Design

AUGUSTUS: Primary Endpoint - Bleeding

AUGUSTUS: Secondary Endpoints

ENTRUST-AF PCI: Study Design

ENTRUST-AF PCI: Primary Endpoint - Bleeding

ENTRUST-AF PCI: Landmark Analysis for Primary Endpoint After Day 14

ENTRUST-AF PCI: Additional Bleeding Outcomes

ENTRUST-AF PCI: Main Efficacy Outcome (ITT Analysis)

Meta-Analysis of 4 NOAC trials in AF + PCI

Patients with AF Undergoing PCI: Meta-Analysis – NOACs vs VKA

ENTRUST-AF PCI: Main Efficacy Endpoint

Clinical Considerations…

What the Experts Say…

Asian Perspective

Recommendations for OAC and Antiplatelet Therapy in AF Undergoing PCI

2019 ESC Guidelines for Chronic Coronary Syndromes

Abbreviations

Abbreviations (cont)